Cladribine
- Generic Name
- Cladribine
- Brand Names
- Litak, Mavenclad
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12ClN5O3
- CAS Number
- 4291-63-8
- Unique Ingredient Identifier
- 47M74X9YT5
- Background
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
- Indication
For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Non-Hodgkin's Lymphomas, Active confirmed by clinical features, confirmed by imaging features relapsing multiple sclerosis (MS)
- Associated Therapies
- -
Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma
- Conditions
- Non-hodgkin LymphomaHodgkin Lymphoma
- Interventions
- Drug: ChidamideDrug: CladribineDrug: gemcitabineDrug: BusulfanProcedure: Autologous hematopoietic stem cell transplantation
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 30
- Registration Number
- NCT03602131
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
- Conditions
- Acute Myeloid LeukemiaBlasts 10 Percent or More of Bone Marrow Nucleated CellsMyeloproliferative NeoplasmBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveHigh Risk Myelodysplastic SyndromeMyeloid SarcomaPhiladelphia Chromosome Positive
- Interventions
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT03589729
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation
- Conditions
- Langerhans Cell Histiocytosis
- Interventions
- First Posted Date
- 2018-07-13
- Last Posted Date
- 2023-03-16
- Target Recruit Count
- 12
- Registration Number
- NCT03585686
- Locations
- 🇷🇺
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2018-07-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 145
- Registration Number
- NCT03586609
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: CladribineDrug: CytarabineDrug: Gemtuzumab OzogamicinBiological: Recombinant Granulocyte Colony-Stimulating FactorOther: Laboratory Biomarker AnalysisDrug: Mitoxantrone Hydrochloride
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 66
- Registration Number
- NCT03531918
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Epacadostat, Cladribine and Cytarabine (ECC) in AML
- First Posted Date
- 2018-04-09
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Registration Number
- NCT03491579
- Locations
- 🇨🇭
Departement of Medical Oncology, University Hospital Berne, Berne, Switzerland
Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 26
- Registration Number
- NCT03441048
- Locations
- 🇺🇸
Froedtert Hospital and the Medical College of Wisconsin, Milwuakee, Wisconsin, United States
CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML
- Conditions
- High Risk Acute Myeloid LeukemiaAllogeneic Hematopoeitic Stem Cell Transplantation
- Interventions
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 120
- Registration Number
- NCT03384212
- Locations
- 🇨🇳
Shanghai general hospital, Shanghai Jiaotong university school of medicine, Shanghai, Shanghai, China
CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML
- Conditions
- Allogeneic Hematopoeitic Stem Cell TransplantationHigh Risk Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 120
- Registration Number
- NCT03384225
- Locations
- 🇨🇳
Shanghai general hospital, Shanghai Jiaotong university school of medicine, Shanghai, Shanghai, China
Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT03318419
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.